(Q36443895)

English

Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis (English)

1 reference

Europe PubMed Central

14 August 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Qiang Fu

1

1 reference

Europe PubMed Central

14 August 2017

Yuan Chang

2

1 reference

Europe PubMed Central

14 August 2017

Huimin An

3

1 reference

Europe PubMed Central

14 August 2017

Hangcheng Fu

4

1 reference

Europe PubMed Central

14 August 2017

Yu Zhu

5

1 reference

Europe PubMed Central

14 August 2017

Le Xu

6

1 reference

Europe PubMed Central

14 August 2017

Weijuan Zhang

7

1 reference

Europe PubMed Central

14 August 2017

Jiejie Xu

8

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

10 November 2015

1 reference

Europe PubMed Central

14 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

14 August 2017

113

1 reference

Europe PubMed Central

14 August 2017

11

1 reference

Europe PubMed Central

14 August 2017

1581-1589

1 reference

Europe PubMed Central

14 August 2017

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

10 November 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1038/bjc.2015.379

0 references

EAU guidelines on renal cell carcinoma: 2014 update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Cancer statistics, 2015

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Interleukin-6 and its receptors: a highly regulated and dynamic system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

IL-6 as an intracrine growth factor for renal carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Expression of the interleukin 6 receptor in primary renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

A method of comparing the areas under receiver operating characteristic curves derived from the same cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

30 September 2017

A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

21 September 2018

Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

21 September 2018

Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

21 September 2018

Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter da

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

21 September 2018

Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

21 September 2018

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

21 September 2018

An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4705889

21 September 2018

Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.379

21 January 2018

ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/26554658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator

1 reference

https://pubmed.ncbi.nlm.nih.gov/26554658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk

1 reference

https://pubmed.ncbi.nlm.nih.gov/26554658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26554658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of tumor-derived IL-1β and IL-18 in localized renal cell carcinoma: Associations with recurrence and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/26554658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2015.379

1 reference

Europe PubMed Central

14 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36443895&oldid=1854591856"